原始出處紀錄
決策級主要結果 (Topline)
Quince Therapeutics：eDSP 用於 A-T 的第 3 期 NEAT 頂線數據預計於 2026 年第一季公布
該公司已完成關鍵性第 3 期 NEAT 試驗的收案（共 105 名受試者），並確認頂線結果將於 2026 年第一季公布。該試驗仍受 FDA 特別方案評估約束，若數據正面，將支持預計於 2026 年下半年提交的 NDA 申請。
關鍵事實
來源摘錄
EX-99.1 2 qncx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Quince Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results Pivotal Phase 3 NEAT clinical trial evaluating lead asset, eDSP, for the treatment of A-T remains on track with topline results expected in first quarter of 2026 SOUTH SAN FRANCISCO, Calif. – November 12, 2025 – Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today provided an update on the company’s development pipeline and reported financial results for the third quarter ended September 30, 2025. Dirk Thye, M.D., Quince’s Chief Executive Officer and Chief Medical Officer, said, “Quince remains on track to report